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Microsporidia have become increasingly recognized as opportunistic pathogens since the genesis of the AIDS
epidemic. The incidence of microsporidiosis has decreased with the advent of combination antiretroviral therapy but it is
frequently reported in non-HIV immunosuppressed patients and as a latent infection in immunocompetent individuals.
Herein, we describe an HIV-infected male (46 years) with suspected progressive multifocal leukoencephalopathy that
has not responded to optimal antiretroviral therapy, steroids, or cidofovir. Post-mortem examination revealed cerebral
microsporidiosis. No diagnostic clue however, was found when the patient was alive. This report underscores the
need for physicians to consider microsporidiosis (potentially affecting the brain) when no other etiology is established
both in HIV, non-HIV immunosuppressed patients and in immunocompetent individuals.
Keywords: Microsporidiosis, Cerebral lesions, HIV, Progressive multifocal leukoencephalopathyCase report
A 46-year-old homosexual male presented at the emer-
gency room on February 22, 2002 for a 5-month pro-
gressive visual impairment, headache and occurrence of
right hemiparesis in the last week.
He was diagnosed with HIV infection in December
1987. His past history was not significant except for vari-
cella in July 1996. At this previous time, his CD4+ count
was 650 cells/μL (24%) with a CD4+/CD8+ ratio of 0.37.
In July 2000 and November 2001, the CD4+ cell counts
were 420 and 330 cells/μL, respectively. No HIV-1 viral
load measurements were available for these dates. Until
he was admitted to our hospital, the patient had declined
any antiretroviral therapy.
At admission, he was afebrile and his physical examin-
ation was unremarkable except for right hemi paresis
and left homonymous hemianopsia. His complete blood
count (CBC), liver function tests and routine biochem-
istry were within normal limits. The CD4+ count was* Correspondence: emil.maude@sympatico.ca; emil.toma@umontreal.ca
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unless otherwise stated.340 cells/μL (16%) with a CD4+/CD8+ ratio of 0.20. A
brain CT-Scan and a magnetic resonance imaging (MRI)
revealed multifocal coalescent lesions with no mass effect
and very little or no enhancement in the white matter
of upper left parietal and left occipital, right temporal
and frontal lobes with cerebral atrophy, suggestive of pro-
gressive multifocal leukoencephalopathy (PML) (Figure 1,
panels a and b).
Serologic tests for syphilis (RPR and Treponema/
TP-PA), EBV-VCA IgM, toxoplasmosis (IgG and IgM) and
search for cryptoccoccal antigen were negative.The patient
had positive results for EBV–EBNA-1 IgG, CMV IgG,
hepatitis C (anti HCV), hepatitis A, anti HBs, antiHBc.
The HBs Ag was negative. He was started on AZT
300/3TC 150 mg (Combivir®) BID and lopinavir 200/
ritonavir 50 mg (Kaletra®) 2 tablets BID. The HIV viral
load was not performed (for technical reasons) before
initiating antiretroviral therapy, but after two weeks it
was 2 279 (3.36 log10) HIV-1 RNA copies/ml. Because of
clinical deterioration, dexamethasone was initiated on
March 15, 2002, and continued until April 8, 2002. Since
no clinical improvement was apparent, i.v. cidofovir
(5 mg/kg) and probenecid twice at one week intervals,
then every 2 weeks were started on April 11, 2002 and
continued until February 3, 2003. His immune statusl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Brain magnetic resonance imaging (panels a and b) and light microscopy findings on brain specimens from autopsy (panels c
and d). Panel a. Axial T2-weighted magnetic resonance image (MRI): multifocal T2 hyperintense subcortical lesions with u-fiber involvement and
no mass effect. Panel b. T1-weighted MRI with Gadolinium: lesions are hypointense. The frontal lesion shows very little peripheral enhancement.
Panel c. Brain section-hematoxylin-eosin × 400: white matter showing two clusters of blue, oval shaped microsporidia surrounded by macrophages.
Panel d. Brain section-hematoxylin-eosin × 400: microsporidia with the characteristic extruded polar tube.
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440 (26%) with a CD4+/CD8+ ratio of 0.38, whereas the
viral load decreased to 91 HIV-1 RNA copies/mL. More-
over, the patient reported a subjective improvement of
his right hemiparesis. On June 26, 2002, AZT was re-
placed by D4T to avoid anemia due to AZT and probene-
cid interaction.
The patient was again hospitalized on August 22, 2002
for fever (39°C), seizures and status epilepticus, necessitat-
ing admission to the Intensive Care Unit (ICU), for intub-
ation and mechanical ventilation. Anti-convulsive therapy
with phenytoin and lamotrigine was then initiated.
Laboratory analysis revealed this time a CD4+ count
of 380 (21%) with a CD4+/CD8+ ratio of 0.38 and a
HIV viral load below the limit of detection (<50 HIV-1
RNA copies/mL). The brain lesions had not changed
since the previous brain MRI. A lumbar puncture was
performed on August 23, 2002. The cerebrospinal fluid
(CSF) examination revealed proteins 0.53 g/L (normal
0.1-0.5), and glucose 4.3 mmol/L (normal 2.2-3.9). Tests
for viral DNA of Poliomavirus JC, BK virus, CMV, PCR
for herpes group viruses (HSV-1, HSV-2, VZV, CMV,
EBV, and HHV-6/7-8), Mycobacterium tuberculosis, and
search for cryptococcal antigen and VDRL all remained
negative in CSF. Plasma CMV DNA, urine cultures,
blood cultures for bacteria, Mycobacteria and fungi were
negative.An ophthalmologic examination confirmed bilateral
blindness of the central origin, but showed no retinitis,
keratoconjonctivitis or deep corneal stromal infection.
He was discharged on September 19, 2002, and was seen
every two weeks at the Ambulatory Unit. On September
23, 2002 his HIV viral load was again below the limit
of detection; CD4+ count was 350 cells/μL (22%) and
CD4+/CD8+ ratio was 0.36.
Despite an optimal control of HIV infection and con-
tinuous combination antiretroviral therapy (cART), the
patient’s status did not improve and he was re-admitted
to the ICU for status epilepticus on April 28, 2003, intu-
bated and mechanically ventilated. A subsequent brain
MRI showed no change as compared with the previous
examinations, but was still suggestive of PML. At admis-
sion, lactic acid and CK levels, as well as platelet count,
remained within normal limits. AST and ALT were
slightly elevated: 65 and 67 U/L respectively. While in
the ICU, the patient developed multiorgan failure with
rhabdomyolysis (CK 47,500), elevated liver enzymes
(AST 2 557 U/L), elevated LDH (4 070 U/L) and dis-
seminated intravascular coagulation: thrombocytopenia
(12 × 109/L), diminished fibrinogen levels, increased
prothrombin time (INR). Lactic acid levels rapidly in-
creased to 17.11 mmol/L on April 29, 2003 before he
expired. Rhabdomyolysis and lactic acidosis were probably
the consequences of repeated muscular convulsions. Blood
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cryptococcal antigen was again negative. Permission
for post mortem examination was obtained.
At macroscopy, the cerebral hemispheres were unre-
markable. The circle of Willis showed a normal archi-
tecture without significant arteriosclerotic lesions.
Leuko-encephalopathic lesions associated with secondary
atrophy predominantly localized in the white matter were
noted. These lesions were multifocal and bilateral, the
largest observed in the orbito-frontal lobes. Another grey
lesion measuring 0.8 × 0.6 cm, which differed from the
leuko-encephalopathic lesions was noted in the right
internal pallidal nucleus. The corpus callosum had sec-
ondary atrophy. Transverse sections of the brain stem
showed atrophy of the right bulbar pyramid. Sagittal sec-
tions of cerebellum revealed ill-demarcated grey areas
within and around dentate nuclei.
At microscopic examination, cerebral microsporidiosis
was documented affecting predominantly the white mat-
ter (mostly on the right side) of the orbito-frontal lobes
with central, right temporo-parietal and cerebellum ex-
tension and a right internal pallidal abscess. Intracellular
clusters of microsporidial spores were found, some of
them with tubular extensions (Figure 1 panels c and d).
In addition, a generalized severe anoxic ischemic en-
cephalopathy was noted. Numerous microscopic foci of
wallerian degeneration of the perivascular white matter,
predominantly fronto-temporo-parietal, compatible with
cerebral arterial ischemia were evidenced. No suggestive
criteria for PML, such as oligodendrocytic inclusions
(Papova type) or reactive dysmorphic gliosis were noted;
the immunoreactivity for simian virus (SV) 40 was ab-
sent. Furthermore, the absence of giant multinucleated
cells rendered a diagnosis of HIV encephalopathy im-
probable. Nonetheless, several extensively calcified small
arteries as noted in HIV encephalopathy were present.
No immune reactivity to anti Toxoplasma antibodies was
present. The Grocott and PAS stainings were negative.
The PCR for JCV on brain tissue was not performed.
Discussion
Microsporidia are widely recognised pathogens in both
invertebrates and vertebrates [1]. Microsporidia belong
to the phylum Microsporidia, with more than 144 genera
and 1200 species [1,2]. The most common human path-
ogens are: Encephalitozoon, Enterocytozoon, Pleistophora
and Nosema.
Microsporidia are small (1.5-2.5 μm × 2.5-4 μm), oval
shaped, obligate intracellular microorganisms found in
epithelial and endothelial cells, fibroblasts, macrophages,
astrocytes [1,2]. Although their human pathogenic po-
tential has been reported, they have become increasingly
recognized as opportunistic pathogens with the advent
of the AIDS epidemic [2]. Initially, Enterocytozoon bieneusiwas identified as a cause of diarrhoea and Encephalitozoon
(E.) intestinalis (formerly Septata intestinalis), and E. cuni-
culi for diarrhoeal or disseminated illnesses [2,3].
Microsporidial hepatitis, sclerosing cholangitis, peri-
tonitis, cardiac, sinusal, urinary, pulmonary, renal or
ocular involvement have been reported [3]. Microsporidia
have been detected in clinical samples from intestines,
livers, muscles, corneas, kidneys, adrenals, gonads, ganglia,
small arteries, biliary tracts, urine, sinuses, and brain [4,5].
Whereas the incidence of microsporidiosis has decreased
in HIV-infected people since the availability of cART, this
infection has been increasingly reported in non-HIV-
infected individuals, such as solid organ and bone marrow
transplant recipients, as well as in cancer, diabetic and eld-
erly patients [6]. Furthermore, microsporidiosis has even
been reported in immunocompetent persons [6,7] and in
solid organ transplant recipients of latently infected donors
[8]. We decided to report this case 12 years later because
of this new emerging evidence and increased interest.
Moreover, we now seek to alert physicians to potentially
include microsporidiosis in the differential diagnosis not
only in HIV-infected patients.
Cerebral microsporidiosis was first reported in 1959
[cited by reference 5] and 12 cases due to E. cuniculi, all
in HIV-infected persons, can be found in the medical lit-
erature from 1991 to 1998 [9]. Several other cases were
described in immunosuppressed, transplant recipients
and HIV-infected individuals [6,10]. In addition, one
case was reported in an immunocompetent patient, dis-
playing hemiparesis and epilepsy [7]. Some diagnosed
patients benefited from treatment with albendazole, which
is active against E. cuniculi [11].
In this case report, cerebral microsporidiosis was doc-
umented post mortem by morphologic examination of
brain samples. Interestingly, this diagnosis was not ini-
tially considered when the patient was living. The patient
presented with no other clinical manifestations such as
diarrhea, keratoconjunctivitis, sinusitis, cholangitis, hepa-
titis, renal injury, which may have suggested a microspori-
dial infection. In addition, his CD4+ count at admission
and 2 months prior was greater than 330 cells/μL in the
absence of antiretroviral therapy. Moreover, the brain CT-
Scan and MRI findings were suggestive of PML [12].
Unfortunately, no tests for microsporidia were per-
formed and no treatment was initiated while the patient
was living, thus, there was no logical reason to suspect
microsporidiosis. At necropsy, no other techniques, such
as tissue culture, monoclonal antibodies staining, PCR
amplification of ribosomal RNA or DNA were performed
to identify and characterize the implicated microsporidian
species.
It is unclear as to how and when the patient acquired
this infection. Microsporidiosis can be transmitted by a
respiratory route, contaminated water or food, contact
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brates or by contact with an infected person [2]. In spite
of well-preserved CD4+ counts and CD4+/CD8+ ratios,
this patient presented with diminished CD16+56+ cell
counts (10–60 cells/μL; normal 130–700) - the main
subpopulation of natural killer (NK) cells. This reduced
cell count may have, in part, contributed to his illness.
Unfortunately, this finding was not considered during
his hospitalisations. Although the T-cell mediated re-
sponses are the main protective mechanisms against
microsporidiosis, the NK cells may contribute to the im-
mune response and control of this infection [13].
There is growing evidence that latent microsporidiosis
is common in immunocompetent individuals and could,
therefore, be reactivated during immunosuppression,
such as in HIV-infected and immunosuppressed persons,
the elderly, transplant recipients, as well as in patients
with malignancies or diabetes [6,14]. It is, therefore,
possible that our patient experienced a reactivation of
latent microsporidiosis that he had acquired before be-
coming HIV-infected. The diminished CD16+56+ cell
counts may likely be responsible, at least in part, for the
reactivation.
We would suggest that cerebral microsporidiosis should
be considered in the differential diagnosis of brain lesions
in HIV-infected as well as in other immunossupressed pa-
tients or transplant recipients, particularly when the eti-
ology is unknown. We would suggest that urinary and CSF
specimens should be submitted for detection of Micro-
sporidia. A pre-emptive treatment with albendazole may
be considered when the brain lesions do not improve des-
pite optimal HIV control, improved immunity and treat-
ment for other suspected brain lesions.
Collectively, given the ubiquitous nature of microspor-
idia; their multiple routes of transmission; the potential
that a latent infection may be reactivated or transmitted
through donated organs; and the multitude of clinical
manifestations, this infection should be considered in
the differential diagnosis, when no definite etiology is
established.
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